Pharmaceutical Industry News Archive
Get news by email or subscribe to our news feeds.
News Archive for July 2010
July 1, 2010
- Santarus Announces Launch of Prescription ZEGERID Authorized Generic and Company Restructuring
- Biogen Idec Names George Scangos Chief Executive Officer
- GSK and Aptuit Finalize Agreement for Aptuit to Acquire GSK's Research Operations in Italy
- Martek Biosciences Announces Restructuring Plans for Winchester, Ky., Manufacturing Site
- GSK To Vacate Buildings, Consolidate Employees
- Shionogi Announces Reorganization of US Operations, New Leadership
- FDA Sends Shire Letter Over Intuniv Promotional Material
- Arena Eyes Marketer for Obesity Drug
- GlaxoSmithKline Sells Italian Research Center
July 2, 2010
- FDA Says Intuniv Promotional Materials are 'Misleading'
- Hi-Tech Pharmacal Temporarily and Voluntarily Suspends Sales of Certain Products
- Lilly to Acquire Alnara Pharmaceuticals
- Genentech Posts New Avastin Ovarian Cancer Results
- Watson Gets Approval for Generic Transplant Drug
- Abbott Laboratories Says Pharma Chief To Retire
- GlaxoSmithKline Amends Deal With Genmab
- Grassley Asks Drug makers How They Treat Whistleblowers
- Eli Lilly Acquires Biotech Drug Developer Alnara
- Olivier Bohuon Joins Pierre Fabre
- Cutting Drug Prices Can Hamper Development of New Medicines, Shows New Study By ESMT Competition Analysis
- NORD Calls for Statement of Policy on Orphan Drug Development
July 5, 2010
- Drug Web Sites May Not Be That Helpful
- New Inspire CEO Shakes Up Leadership
- Statement by FTC Chairman Jon Leibowitz Regarding House Passage of Legislation To Stop Costly Pay-for-Delay Drug Settlements
July 6, 2010
July 7, 2010
- European Commission Approves ORENCIA in Combination with Methotrexate for Earlier Use as First-Line Biologic after DMARD Inadequate Response for the Treatment of Rheumatoid Arthritis
- SDI Reports: Novo Nordisk Takes Top Ranking Among Endocrinologists, According to Pharmaceutical Company Image Study
- GSK, Xenoport Migraine Candidate Fails
July 8, 2010
- Genzyme Expands Manufacturing Deal With Hospira
- Alcon Independent Director Committee Announces Creation and Funding of Litigation Trust
- Crucell N.V. (NL) - Crucell Reaches Agreement with Sanofi Pasteur on Programs in the Field of Paediatric and Respiratory Vaccines
- Four Pfizer Medications On FDA Watch List
- Alcon Starts Lawsuit Trust, Focuses On Novartis
- Merck Details Plans to Advance Integration of R&D, Manufacturing and Business Operations Worldwide
- BYU Widens Pfizer Fraud Complaint
- NIH-Led Scientists Find Antibodies That Prevent Most HIV Strains from Infecting Human Cells
July 9, 2010
- NIH Scientists Discover HIV-Fighting Antibodies
- FDA Poised To Release Report On Maligned Drug Avandia
- Merck Germany Exec To Become Millipore's Chief
- Merck Germany Exec To Become Millipore's Chief
- European Medicines Agency starts review of rosiglitazone-containing medicines
- Shire Files Patent Lawsuit Against Cadila
- K-V Pharma Could Be Delisted Due To Late Report
July 12, 2010
- PharmaLive Analyzes Drugs And Devices In Development For Oncology, The Leading Therapeutic Area Globally
- Drug Makers Told: Give Risks Equal Billing
- Johnson & Johnson Announces Definitive Agreement to Acquire Micrus Endovascular
- Cancer Drug Olaparib Shows Early Promise
- Auxilium Says 2Q Xiaflex Sales Grew To $3.1M
July 13, 2010
- Alzheimer's Association Launches TrialMatch
- Vivus Shares Fall Ahead Of Review For Obesity Drug
- Equity and excellence: Liberating the NHS
- Report: Avandia Drug Maker In Coverup
- John J. Castellani to Lead PhRMA as New President & CEO
- Eli Lilly Will Shed 170 Jobs In Manufacturing, Quality Control
July 14, 2010
- FDA Drug Safety Communication: New Boxed Warning for Severe Liver Injury with Arthritis Drug Arava (leflunomide)
- Former Pfizer Senior Vice President Named CEO of Berlin Pharmaceutical Industry in a Partnership to Diversify and Expand Company Business in Asia
- Bristol-Myers Squibb Initiates a Nationwide Voluntary Recall of Coumadin 1 mg Tablet Blister Packs
- GlaxoSmithKline Statement in Response to FDA Advisory Committees' Vote on Safety of Avandia (rosiglitazone)
July 15, 2010
- Glaxo Takes $2.36 Billion Charge on Legal Costs
- Novartis International AG (CH) - Novartis delivers strong financial performance in second quarter, underpinned by increased momentum in innovation
- Takeda Responds to FDA Advisory Committee Recommendation
- FDA Panel Says Avandia Should Stay On Market
- Mylan to Acquire Bioniche Pharma Global Injectable Pharmaceuticals Business
- Former Mylan Fleet Manager Indicted For Fraud
- John Weyrauch and Martin O?Brien Join Rosetta as Partners in Healthcare Group
- Novartis Says 2Q Net Profit Up 19% to $2.44 Billion
- Obesity Drug Makers Shares Rise on Study
- Prevention Magazine Finds Consumers Believe Pharmaceutical Advertising in Magazines and TV is Fair and Balanced?But Less So Online via 13th Annual ?Consumer Reaction to DTC Advertising of Prescription Drugs?
- K-V Pharmaceutical Names Thomas McHugh Chief Financial Officer
- Cardinal Health Completes Acquisition of Healthcare Solutions Holding
- Merck KGaA, Darmstadt, Germany Completes Millipore Acquisition and Launches New EMD Millipore Division (Merck Millipore Division outside U.S. and Canada)
- Adolor Corporation Announces Restructuring
July 16, 2010
- Elan to Settle Zonegran Investigation For $204 Million
- Adolor to Cut 30 Jobs as Entereg Sales Disappoint
- Diamyd Medical: Diamyd Agreement Receives Antitrust Clearance
- Elan Corporation, plc Reaches Agreement in Principle for Settlement of Investigation of Past Zonegran Sales and Marketing Activities
- Okla. Joins Wyeth Drug Pricing Case
- Lilly Cutting 340 IT Jobs
- K-V Pharma Replaces CFO After 3 Months
- Watson Licenses Hormone Drug Candidate From Itero
- Elan to Settle Zonegran Investigation for $204 Million
- Adolor to Cut 30 Jobs as Entereg Sales Disappoint
- Sanofi-Aventis, Novalar Request Oraverse Approval
- Millipore Corporation Announces Effective Date of Make-Whole Fundamental Change and Increase in Conversion Rate Due to Make-Whole Fundamental Change Relating to Its 3.75% Convertible Senior Notes Due 2026
- FDA Warns Consumers, Pharmacists, and Wholesalers Not to Use Stolen Advair Diskus Inhalers
July 19, 2010
- FDA Warns Of Stolen Inhalers' Safety
- ISMPP Reiterates Progress in Medical Publications in Response to Senator Grassley's Report
- Nycomed's U.S. Patent for Protonix (pantoprazole) Valid
- Phase 3 Open-Label Study Comparing Tapentadol Extended Release Tablets to Oxycodone Controlled Release Tablets Published by Pain Practice
- District Court Upholds Patent On Pfizer's Protonix
- Pfizer Suspends Chronic Pain Studies in Tanezumab Clinical Trial Program; Some Studies Continue in Areas of Unmet Medical Need
July 20, 2010
- Mylan Gets Approval For High Blood Pressure Patch
- Biogen Idec Reports Second Quarter 2010 Results
- Johnson & Johnson Reports 2010 Second-Quarter Results:
- Johnson & Johnson Reports 2010 Second-Quarter Results:
- Forest Laboratories, Inc. Reports First Quarter FY 2011 EPS of $0.39, Including $0.39 Per Share Charge Related to Settlement in Principle with US Department of Justice and $0.17 Per Share Charge for New Product Licensing Fee
- Biogen Second Quarter Profit Doubles Without Acorda Payment
- US Panel: Study Showed No Benefit With Avastin
July 21, 2010
- Gilead 2Q Profit Rises But Misses Street View
- Lilly Announces Completion of Alnara Acquisition
- Gilead Sciences Announces Second Quarter 2010 Financial Results
- Abbott Reports Strong Second Quarter Results; Confirms Double-Digit Ongoing Earnings Growth Outlook for 2010
- Daiichi Sankyo to Leverage Ranbaxy?s Network to Market Its Innovative Antibiotic Tavanic (Levofloxacin) in Romania and South Africa
- Genzyme Reports Financial Results for the Second Quarter of 2010
- GSK Announces Q2 Results for 2010
July 22, 2010
- FDA Statement on Avandia TIDE Trial
- Baxter Reports Second Quarter Financial Results in Line with Guidance
- Bristol-Myers Squibb Second Quarter Featured Robust Clinical Data and Double-Digit EPS Growth
- Lilly Reports Strong Second-Quarter 2010 Results
- US Agency Puts Hold On Much-Debated Avandia Study
- Eli Lilly Beats Estimates, Raises Forecast
- Huge New Suit Against Pfizer May Emerge In Nigeria
- Roche posts good half year results
- Bristol-Myers Squibb Misses Revenue Estimates
- IMS Expands Oncology Analyzer Offering in China, Providing Comprehensive Treatment Insights for Enhanced Commercial Decision Making
- Expert Challenges FDA to Bring Predictability, Feasibility, and to Drugs Risk Management Process
July 23, 2010
- EB Pays $55 Million For Pfizer Site
- Cialis' Success Fuels Lilly Push For New Men's Health Drugs
- FDA Was Stymied In Records Search At Johnson And Johnson Plant
- Forest Settles Patent Dispute Over Namenda
- European Medicines Agency recommends restricting the use of modafinil
July 26, 2010
- Almirall signs a co-promotion agreement with Pfizer to commercialise Conbriza in Spain, a new therapeutic option to treat osteoporosis
- FDA Approves Larger Dose Of Pfizer's Aricept
- Gilead to Offer $2.2 Billion of Convertible Senior Notes; Company to Repurchase $1 Billion in Common Stock
- Sanofi-Aventis, Genzyme Discuss Possible Acquisition: Wall Street Journal
- FTC Pushed Watson Subpoena, Denies Info Disclosure
- Onyx Posts Positive Results For New Cancer Drug
July 27, 2010
- Alcon Posts 12.5 Percent Rise in Second Quarter Sales
- Teva Reports Strong Second Quarter 2010 Results Driven by Growth in All Businesses
- Teva 2Q Profit Climbs 53 Percent
- GSK to Revamp Basis for Bonuses
- FDA Questions New Astrazeneca Blood Thinner
- Alcon's Net Profit Up To $670 Million In Second Quarter
- Court Places No Restrictions On Generic Lovenox
- Momenta Pharmaceuticals Provides Update Regarding Generic Lovenox Litigation
- Millipore Corporation Announces Change of Control and Right of Holders to Require Purchase of Its 5.875% Senior Notes Due 2016
July 28, 2010
- Pfizer Starts Social-Media Channel On Popular Site
- Wyeth Hormone Drug Case Opens In Philadelphia
- FTC Testimony: Stopping ?Pay-for-Delay? Drug Settlement Agreements is a Top Competition Priority
- Astellas to Pay $295 Million to Extend License of Regeneron's VelocImmune(R) Antibody Technology through 2023
July 29, 2010
- Sanofi-Aventis Q2 Net Up 61 Percent
- Astrazeneca Q2 Profits Up 22 Percent
- Q2/2010: Merck KGaA Profit After Tax Jumps 70% to EUR 187 Million
- Bayer Increases Sales And Earnings In The Second Quarter
- AstraZeneca 2Q Profit Up 22 Pct
- Sanofi-Aventis Q2 Net Up 61 Percent
- Appeals Court Rules Gemzar Patent Invalid
- Sanofi Said to Be Preparing Genzyme Bid
- FDA MedWatch - Cubicin (daptomycin): Drug Safety Communication - Risk of Eosinophilic Pneumonia
July 30, 2010
- Novartis Vaccines Launches Fluvirin Vaccine in US Market
- FDA Advisory: Avoid Unintentional Exposure of Children and Pets to Evamist
- FDA Advisory: Avoid Unintentional Exposure of Children and Pets to Evamist
- Merck Announces Second-Quarter 2010 Financial Results
- Amgen's Second Quarter 2010 Adjusted Earnings Per Share Increased 7 Percent to $1.38
- Novartis Vaccines Launches Fluvirin Vaccine in US Market
- Charles River Announces Mutual Termination of Acquisition Agreement with WuXi PharmaTech
- Conatus Pharmaceuticals Acquires Pfizer's Idun Subsidiary
